CD8A and neoplasm: CTLA-4 will bind to CD 80 or CD 86 receptor (also known as B7) on antigen presenting cells (APCs) with higher affinity than the CD28 receptor on CD4+ and CD8+ T cells, which will suppress costimulatory signals and inhibit activation of the helper and cytotoxic T cell response against the tumor [83,85].